Molecular structure of Encorafenib, CAS Number: 1269440-17-6
Encorafenib (CAS 1269440-17-6)
Alternate Names:
LGX818
CAS Number:
1269440-17-6
Molecular Weight:
540.01
Molecular Formula:
C22H27ClFN7O4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Encorafenib (CAS 1269440-17-6) References
- Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma. | Trouiller, JB., et al. 2024. Eur J Health Econ. 25: 641-653. PMID: 37433888
- SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. | Elez, E., et al. 2024. Future Oncol. 20: 653-663. PMID: 37815847
- BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. | Dinter, L., et al. 2024. Int J Cancer. 154: 1057-1072. PMID: 38078628
- Disseminated intravascular coagulation induced by the combination therapy of encorafenib and binimetinib in a melanoma case. | Komatsu, S., et al. 2024. J Dermatol. 51: e218-e219. PMID: 38293725
- Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration. | Piscitelli, J., et al. 2024. Clin Pharmacokinet. 63: 483-496. PMID: 38424308
- Prediction of cytochrome P450-mediated bioactivation using machine learning models and in vitro validation. | Hu, XM., et al. 2024. Arch Toxicol. 98: 1457-1467. PMID: 38492097
- A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. | Baik, C., et al. 2024. Adv Ther. 41: 2586-2605. PMID: 38698170
- COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. | Schadendorf, D., et al. 2024. Eur J Cancer. 204: 114073. PMID: 38723373
- Mass Spectrometry-Based Proteomics Analysis Unveils PTPRS Inhibits Proliferation and Inflammatory Response of Keratinocytes in Psoriasis. | Zheng, X., et al. 2024. Inflammation.. PMID: 38739342
- Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function. | Bromberger, S., et al. 2024. Life Sci Alliance. 7: PMID: 38839106
- BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab. | Imai, T., et al. 2024. CNS Oncol. 13: 2347824. PMID: 38869444
- Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. | Piscitelli, J., et al. 2024. Cancer Chemother Pharmacol.. PMID: 38878209
- BRAF-mutant microsatellite-stable rectal cancer with acquired KRAS mutation leading to drug resistance in liver metastasis. | Shigeyasu, K., et al. 2024. Int Cancer Conf J. 13: 189-192. PMID: 38962037
Inhibitor of:
BBS8, Brk, FAM149B1, Gm9766, gp100, KIAA1549, MAGE-C3, Melan-A, Melanoma Marker, Olr1064, Olr113, Olr1156, Olr309, Olr541, Olr653, Olr728, Raf-1, Raf-B, RSPRY1, SNFT, SS18L2, and TMEM170B.Activator of:
Melanoma.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Encorafenib, 1 mg | sc-507422 | 1 mg | $115.00 |